We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Vels Institute of Science, Technologies & Advanced Studies, P.V Vaithiyalingam road, old Pallavaram, Chennai-600117, Tamilnadu, India.
Community-acquired pneumonia (CAP) continues to represent a significant cause of morbidity and mortality worldwide. Antibiotic therapy is fundamental to its management, with various regimens incorporating beta-lactams, macrolides, and fluoroquinolones frequently utilized. This prospective observational study aimed to evaluate the efficacy of three distinct antibiotic regimens in the treatment of CAP. A total of 96 patients diagnosed with CAP were enrolled and divided equally into three groups: beta-lactam, macrolide, and fluoroquinolone. The study was conducted over six months and assessed clinical outcomes, including fever resolution, length of hospital stay, and adverse effects, in conjunction with patient demographics. The findings suggest that while all regimens demonstrated effectiveness, notable differences in patient outcomes were observed, underscoring the necessity for tailored treatment strategies.
Community-acquired pneumonia (CAP) represents a significant global health concern. It is a leading cause of hospitalization and mortality, particularly among the elderly and individuals with comorbidities. Antibiotics serve as the primary treatment for CAP, with a variety of regimens available for consideration. The selection of an appropriate antibiotic is influenced by several factors, including the severity of the infection, the patient's underlying health conditions, and local resistance patterns. This study aims to compare the efficacy of three commonly used classes of antibiotics: beta-lactams, macrolides, and fluoroquinolones, in the treatment of CAP.
This observational study was carried out over a duration of six months. The aim was to assess the effectiveness of three different antibiotic treatment regimens for patients diagnosed with community-acquired pneumonia..
This Study included 96 patients who were diagnosed with community-acquired pneumonia (CAP). These patients were randomly assigned to one of three treatment groups:
2.4 Exclusion Criteria
2.5 Demographics
The study included a diverse sample in terms of age, gender, and comorbid conditions:
2.6 Intervention
The antibiotic regimens were administered according to standard clinical guidelines:
2.7 Outcome Measures
The primary outcomes assessed included:
Secondary outcomes included:
Descriptive statistics along with comparative analyses, including ANOVA and chi-square tests, were employed to analyze the data. A p-value of less than 0.05 was established as the threshold for statistical significance.
Fluoroquinolones showed the fastest fever resolution.
Fluoroquinolone group had the shortest LOS.
There were no severe adverse effects or discontinuations due to side effects in any group.
During the trial, no patients passed away. However, because of their inadequate response, two patients in the macrolide group needed their medication to be escalated.
This research indicated that all three antibiotic treatment regimens were successful in managing community-acquired pneumonia. Nonetheless, variations were observed in the duration until fever resolution, length of hospital stay, and occurrence of side effects. Fluoroquinolones were linked to a quicker alleviation of symptoms and a reduced hospital stay, highlighting their potential advantages in more severe cases. Beta-lactams also proved effective, exhibiting fewer side effects, although they resulted in slightly longer recovery periods compared to fluoroquinolones.
Macrolides demonstrated effectiveness as well; however, their marginally higher rate of adverse effects and extended recovery times suggest they may not be the optimal first-line option for all patients, particularly those with more severe conditions.
The study underscores the necessity of choosing antibiotics based on patient characteristics, pneumonia severity, and local resistance patterns. Additional large-scale research is required to confirm these results and to investigate the cost-effectiveness and resistance trends associated with these antibiotics in the management of community-acquired pneumonia.
The findings from this prospective observational study indicate that beta-lactams, macrolides, and fluoroquinolones are all effective in the treatment of community-acquired pneumonia. However, fluoroquinolones demonstrate benefits such as faster symptom resolution and reduced hospital duration. This could position fluoroquinolones as a more suitable choice for patients with severe cases of CAP. Nonetheless, it is essential to take into account patient demographics, existing comorbidities, and possible adverse effects when determining the appropriate antibiotic treatment plan.
Declarations
Funding
No funding was received for this review article.
Conflicts of Interest
The authors declare no conflicts of interest.
Ethics Approval
Got Approval from Institutional Ethical Committee. And certificate is attached below.
REFERENCES
S. Sathishkumar, M. Immanuel Jebastine, Comparing the Efficacy of Different Antibiotic Regimens in Treating Community-Acquired Pneumonia: A Prospective Observational Study, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 3, 1141-1147. https://doi.org/10.5281/zenodo.15017447
10.5281/zenodo.15017447